Autonomous vehicle test fleets generate more video than they can store or move. Beamr’s lossless compression keeps footage bit-exact at capture in the test vehicles, while reducing file sizes by 47%.

Join the demonstration at AutoSens Europe, Barcelona, September 22–24, stand 131

Herzliya, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) — Beamr Imaging Ltd. (Nasdaq: BMR), a leader in video optimization technology and solutions, today launched lossless compression as part of ML-Safe video data compression for autonomous vehicles (AV). The ML-Safe solution, enabling AV teams to reduce video data file sizes while preserving ML model accuracy, now covers lossy compression that is confirmed against the model’s own accuracy metrics, and lossless compression that is bit-exact by definition.

Beamr will demonstrate its ML-Safe solution at AutoSens Europe in Barcelona, September 22–24, stand 131.

AV test fleets generate more video than they can store or move. A single test vehicle runs as many as 16 cameras, and 11 is typical. They can record tens of terabytes in one shift. Cameras commonly produce 12-bit Bayer, the camera sensor’s raw output before it enters the AV pipeline. Until now AV teams often had to keep the footage raw, without compression, since the encoder in the test vehicle did not accept the 12-bit Bayer format. As a result, AV teams had two choices: keep the raw footage and pay for it in drives, swaps and upload time, or delete video data and hope a future model never needs it.

Beamr’s lossless compression addresses the AV teams need by taking the 12-bit Bayer and compressing it with zero loss. In addition, data-capture capacity is almost doubled, data is preserved, and no new hardware is needed. The work runs on the video encoder that is integrated in the GPU already in the data logger. Since the encoder runs separately from the GPU compute cores, compression draws on capacity the AI models are not using.

Beamr’s lossless compression is designed to compress multiple cameras in real time on the video encoder of a single GPU. In Beamr’s testing on 12-bit Bayer recordings from 8-megapixel cameras, compressed files were 47% smaller than raw.

“Through our joint work with AV and ADAS companies we identified their need for lossless compression at the edge, in the data-collection vehicle, supporting multiple camera streams in real time. So we built it,” said Sharon Carmel, Beamr CEO. “By running Beamr’s lossless solution accelerated by GPUs, we are demonstrating a solution that reduces the data at the point of capture while preserving every bit of the original camera data.”

“Lossless compression was the piece missing from Beamr’s ML-Safe video data compression solution for AV,” said Dani Megrelishvili, Beamr CPO. “We are already offering ML-Safe lossy compression tested against the team’s own models. Now teams that need every bit kept can also compress in the test vehicle. This puts Beamr at the point where data is created, and what is saved there is saved again at every step that follows: on the drives, on the way to the cloud, and in every training run that reads it.”

Autonomous vehicle and ADAS teams can test Beamr ML-Safe compression on their own video data and pipeline design. To book a meeting at AutoSens Europe, Barcelona (stand 131), or request lossless evaluation on your data, visit beamr.com/lossless.

About Beamr

Beamr (Nasdaq: BMR) is a world leader in content-adaptive video compression, trusted by top media companies including Netflix and Paramount. Beamr’s perceptual optimization technology (CABR) is backed by 53 patents and a winner of Emmy® Award for Technology and Engineering. The innovative technology reduces video file sizes by up to 50% while preserving quality and enabling AI-powered enhancements.

Beamr powers efficient video workflows across high-growth markets, such as media and entertainment, user-generated content, machine learning, and autonomous vehicles. Its flexible deployment options include on-premises, private or public cloud, with convenient availability for Amazon Web Services (AWS) and Oracle Cloud Infrastructure (OCI) customers.

For more details, please visit www.beamr.com or the investors’ website www.investors.beamr.com and follow us on Linkedin and X.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. Forward-looking statements in this communication may include, among other things, statements about Beamr’s strategic and business plans, technology, relationships, objectives and expectations for its business, the impact of trends on and interest in its business, intellectual property or product and its future results, operations and financial performance and condition, including statements relating to the capabilities, performance, applications, market opportunities, adoption, commercialization and potential benefits of the Company’s technology, products and solutions, and the Company’s ability to execute its growth strategy and create commercial opportunities. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on the Company’s current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. For a more detailed description of the risks and uncertainties affecting the Company, reference is made to the Company’s reports filed from time to time with the Securities and Exchange Commission (“SEC”), including, but not limited to, the risks detailed in the Company’s annual report filed with the SEC on February 26, 2026 and in subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of the date hereof and the Company undertakes no duty to update such information except as required under applicable law.

Investor Contact:
investorrelations@beamr.com

ROCHESTER, N.Y., Sept. 16, 2026 (GLOBE NEWSWIRE) — DSS, Inc. (NYSE American: DSS) (“DSS” or the “Company”) today announced that Zoar Limited (“Zoar” or “PubCo”) has filed a Registration Statement on Form F-4 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) in connection with the previously announced proposed business combination (the “Business Combination”) involving Impact Biomedical Inc. (NYSE American: IBO) (“Impact”), Zoar and certain related parties.

DSS is a significant stockholder of Impact Biomedical, and the filing represents an important step in Impact’s proposed Business Combination with Zoar.

“We are pleased to see Impact reach this important milestone in its proposed Business Combination with Zoar,” said Jason Grady, Chief Executive Officer of DSS, Inc. “The filing of the Form F-4 demonstrates continued momentum toward the proposed transaction and represents another step in the evolution of Impact. We believe the combination has the potential to strengthen Impact’s platform, expand its opportunities for future growth, and ultimately create meaningful value for DSS and our shareholders.”

The Registration Statement includes a preliminary proxy statement of Impact and a prospectus of Zoar relating to the proposed transaction. The filing remains subject to SEC review and has not yet been declared effective.

The proposed Business Combination remains subject to a number of conditions, including the Registration Statement being declared effective by the SEC, approval of the transaction by Impact stockholders, approval of the listing of Zoar ordinary shares on NYSE American, and the satisfaction or waiver of other conditions contained in the applicable merger and share exchange agreement.

The filing of the Registration Statement does not mean that the Registration Statement has been declared effective, that the SEC has completed its review, that Impact stockholders have approved the proposed transaction, or that the transaction will be completed.

About DSS, Inc.

DSS, Inc. (NYSE American: DSS) is a multinational company operating across multiple business lines including product packaging, biotechnology, commercial lending, and securities and investment management. The Company operates a business model based on developing high-growth subsidiaries and unlocking value through strategic IPOs and public listings. For more information, visit www.dssworld.com.

Additional Information and Where to Find It

In connection with the proposed Business Combination, Zoar Limited has filed with the SEC a Registration Statement, which includes a preliminary proxy statement of Impact that also constitutes a prospectus of Zoar. Investors and security holders are urged to read the Registration Statement, the proxy statement/prospectus and any other relevant documents filed or to be filed with the SEC, as well as any amendments or supplements to those documents, carefully and in their entirety when they become available because they contain or will contain important information regarding the proposed transaction.

Copies of these documents may be obtained without charge through the SEC’s website.

No Offer or Solicitation

This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities, nor does it constitute a solicitation of any vote, proxy, consent or approval in connection with the proposed transaction. No offer or sale of securities shall be made except in accordance with applicable securities laws.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of applicable federal securities laws. These statements include, among others, statements concerning the proposed Business Combination, the anticipated completion of the transaction, the effectiveness of the Registration Statement, stockholder and regulatory approvals, the proposed listing of Zoar ordinary shares and the anticipated ownership of PubCo following the transaction. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those expressed or implied. DSS undertakes no obligation to update any forward-looking statements except as required by law.

Investor Relations

DSS, Inc.
ir@dssworld.com
+1 (585) 565-2422

HOUSTON, Sept. 16, 2026 (GLOBE NEWSWIRE) — Impact Biomedical Inc. (NYSE: IBO) (the “Company” or “Impact”) announced that a Form F-4 registration statement (the “Registration Statement”) was filed with the U.S. Securities and Exchange Commission (the “SEC”) on Thursday, September 10, 2026, by Zoar Limited (“PubCo”) in connection with the previously announced business combination (the “Business Combination”) with, among others, PubCo and Zoar Labs Limited (f/k/a Dr. Ashley’s Bio Labs Limited) (“Zoar Labs”), which includes Impact’s preliminary proxy statement. The F-4 Registration Statement is available through the SEC’s website at www.sec.gov under the name “Zoar Limited”.

The management of Impact believes the filing of the Registration Statement is a major milestone in the path to closing. The completion of the Business Combination and the listing of the ordinary shares of PubCo shall be subject to, among others, the Registration Statement being declared effective by the SEC, approval of the transaction by Impact stockholders, approval of the listing of PubCo shares on NYSE American, and satisfaction or waiver of the other conditions in the merger and share exchange agreement.

The merger of Impact Biomedical Inc. and Zoar, upon approval and closing, is expected to result in a pharmaceutical company focused on the development and supply of Active Pharmaceutical Ingredients and intermediates for special therapeutic treatment areas.

Additional Information and Where to Find It
In connection with the proposed transaction, Zoar Limited has filed with the SEC a Registration Statement that includes a preliminary proxy statement/prospectus (a “Proxy Statement/Prospectus”). After the Registration Statement is declared effective, a definitive Proxy Statement/Prospectus will be mailed to Impact’s stockholders as of a record date to be established by Impact’s board of directors for voting on the Business Combination. Impact may also file other relevant documents regarding the Business Combination with the SEC. Impact’s stockholders and other interested persons are advised to read, once available, the preliminary Proxy Statement/Prospectus and any amendments thereto and, once available, the definitive Proxy Statement/Prospectus, in connection with Impact’s solicitation of proxies for its special meeting of stockholders to be held to approve, among other things, the Business Combination, because these documents will contain important information about Impact, Zoar Labs, PubCo and the Business Combination. Stockholders of Impact may also obtain a copy of the preliminary or definitive proxy statement, once available, as well as other documents filed with the SEC, without charge, at the SEC’s website located at www.sec.gov or by directing a request to: Impact’s Chief Executive Officer at 275 Wiregrass Pkwy, West Henrietta, NY 14586.

Participants in the Solicitation
Impact, PubCo, Zoar Labs, and their respective directors and executive officers may be deemed to be participants in the solicitation of proxies from Impact stockholders in connection with the proposed transaction. Information about Impact’s directors and executive officers is set forth in Impact’s filings with the SEC. Additional information regarding the participants in the proxy solicitation and a description of their direct and indirect interests, by security holdings or otherwise, is contained in the Registration Statement and the Proxy statement/Prospectus included therein.

About Zoar Ltd:
Zoar Ltd. is a global pharmaceutical company focused on the development and manufacturing of active pharmaceutical ingredients, formulations, orphan drugs, and contract development and manufacturing services for pharmaceutical and biotechnology companies worldwide.

About IBO:
Impact Biomedical Inc. discovers, confirms, and patents unique science and technologies which can be developed into new offerings in biopharmaceuticals and consumer healthcare and wellness in collaboration with external partners through research, licensing, co-development, joint ventures, and other relationships.

Safe Harbor Disclosure:
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, including statements regarding the Registration Statement, the proposed Business Combination, remaining conditions to closing, expected ownership and listing of PubCo shares, and the anticipated combined business. These statements are subject to risks and uncertainties that may cause actual results or events to differ materially from those projected, including the risk that the Registration Statement is not declared effective on the anticipated timeline or at all, that Impact stockholders do not approve the transaction, that NYSE American does not approve the listing of PubCo shares, that other closing conditions are not satisfied or waived, or that the merger and share exchange agreement is terminated. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date of this press release.

No Offer or Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities or in respect of the proposed transaction and does not constitute an offer to sell, or a solicitation of an offer to buy, any securities, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offering of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act of 1933, as amended.

Investor Relations:
info@impactbiomedinc.com
www.impactbiomedinc.com

Webinar Follows Recent Business Update Highlighting 3X Omni One Order Growth and Expanding Defense and Enterprise Opportunities

Virtuix to Host Virtual Investor Webinar on Friday, September 18, 2026, at 10:00 a.m. Eastern Time

AUSTIN, Texas, Sept. 16, 2026 (GLOBE NEWSWIRE) — Virtuix Holdings Inc. (NASDAQ: VTIX), a leading developer of AI-driven, full-body simulation systems, today announced that it will hold a virtual investor webinar on Friday, September 18, 2026, at 10:00 a.m. Eastern Time.

Virtuix Chief Executive Officer Jan Goetgeluk will give an overview of the company’s growth strategy, near-term priorities, and recent commercial successes and developments, including its accelerating consumer momentum, expanding defense programs, and potential strategic acquisition.

In a recent business update, the Company highlighted that the number of Omni One orders are up approximately 3X quarter-to-date compared with the same period last year, following the June launch of Omni One for Quest in collaboration with Meta.

The Company also highlighted progress across multiple U.S. Department of Defense programs; repeat Omni One Enterprise orders from Tesla for its Optimus humanoid robot program; additional enterprise sales to organizations including NASA; and a potential strategic acquisition in the defense sector of a target whose annual revenues are near the upper end of the Company’s previously announced target range of $10 million to $50 million, at a valuation and financing structure that, if completed, the Company believes could create significant value for Virtuix shareholders.

Mr. Goetgeluk will be joined by Mr. David Allan, Virtuix’s President and Chief Operating Officer, and Ms. Lauren Premo, Virtuix’s Chief Marketing Officer. A question-and-answer session will follow.

The virtual investor webinar will be accompanied by a presentation, which can be viewed during the webcast or accessed following the call on the Company’s investor relations website here.

To attend the webinar or watch the replay following the event, please use the following information:

Date: Friday, September 18, 2026
Time: 10:00 a.m. Eastern Time (7:00 a.m. Pacific time)
Registration: https://app.livestorm.co/virtuix/virtuix-investor-webinar-91826

The replay can be viewed through the webinar link that you’ll receive after registration.

Investors who would like to submit their questions in advance can do so by sending them to VTIX@mzgroup.us.

About Virtuix

Virtuix Holdings Inc. (NASDAQ: VTIX) is a developer of AI-driven, full-body immersive simulation systems and the creator of the “Omni” omni-directional treadmill. Virtuix’s technology lets users physically move through virtual and AI-generated environments. The Company’s products are deployed across consumer entertainment, defense training and simulation, robotics, healthcare, research, and enterprise applications involving organizations including NASA, Tesla, KBR, and Sirica Therapeutics. The Company’s growing federal and defense footprint includes programs, deployments, and research initiatives involving the U.S. Army, Marine Corps, Navy, and Air Force.

Virtuix continues to expand the Omni brand from immersive entertainment into a broader, full-body simulation technology platform serving multiple commercial and government markets. For more information, visit virtuix.com or the Company’s new Investor Relations website at invest.virtuix.com.

Cautionary Note Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include, but are not limited to, statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements that are other than statements of historical facts. When the Company uses words such as “may,” “will,” “intend,” “should,” “believe,” “expect,” “anticipate,” “project,” “estimate,” “could,” “would,” “potential” or similar expressions that do not relate solely to historical matters, it is making forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company’s expectations for continued consumer growth following the Meta integration; the timing, completion, funding, or scope of defense programs, including the AFWERX SBIR Phase II proposal and the Infantry Fireteam Trainer installation; the Company’s ability to progress from initial development programs toward larger defense contracts; the Company’s sales and expansion plans; plans to pursue and complete strategic acquisitions, including the potential transaction currently under negotiation; potential impacts of any acquisition on future revenues, operations, or shareholder value; the Company’s competitive position in the defense training market; and the potential for enterprise applications to represent an additional growth market. Forward-looking statements are not guarantees of future performance and involve risks and uncertainties that may cause the actual results to differ materially from the Company’s expectations discussed in the forward-looking statements. These statements are subject to uncertainties and risks including, but not limited to: the Company’s ability to identify, negotiate, and complete acquisitions on favorable terms or at all; the ability to successfully integrate any acquired business and realize anticipated synergies or benefits; risks related to government contracting, including contract cancellations, modifications, delays, or funding changes; uncertainties regarding continued consumer demand and market acceptance of the Company’s products; competition in the VR, gaming, defense, and enterprise markets; dependence on third-party relationships, including the Meta partnership; the uncertainties related to general market conditions; and other factors discussed in the “Risk Factors” section of the Company’s registration statement and other filings with the SEC. For these reasons, among others, investors are cautioned not to place undue reliance upon any forward-looking statements in this press release. Additional factors are discussed in the Company’s filings with the SEC, which are available for review at www.sec.gov. The Company undertakes no obligation to publicly revise these forward-looking statements to reflect events or circumstances that arise after the date hereof.

Visit Us on Social Media:

LinkedIn
Instagram
Facebook
YouTube
TikTok
X

Company Contact
Lauren Premo
Virtuix Inc.
press@virtuix.com

Investor Relations Contact
Chris Tyson
MZ Group
Direct: 949-491-8235
VTIX@mzgroup.us

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/e7cbc54e-c626-4082-bfb5-0e095b1e0096

SALT LAKE CITY, Sept. 16, 2026 (GLOBE NEWSWIRE) — AXG Digital Holdings, LLC (“AXG Digital”), a U.S. subsidiary of SOLOWIN HOLDINGS (Nasdaq: AXG) (together with its subsidiaries, “AXG” or the “Company”), a leading financial technology firm bridging traditional and digital assets, today announced the appointment of key executives to spearhead the Company’s AI and high-performance computing (HPC) infrastructure strategy. 

Mr. Andrew Vickery will join AXG Digital as Chief Executive Officer and Director, leading the development, financing and execution of the Company’s AI and digital infrastructure strategy. Mr. Vickery brings more than two decades of experience across technology, power and infrastructure. At JPMorganChase, he spent six years in project finance across Europe and Asia, where he was involved in more than $20 billion in financings involving power generation and related infrastructure, before later serving as Head of Telecom, Media and Technology for Germany and Austria. He has been involved in technology and AI-related businesses since 2005, when he took a medical imaging company that utilized foundational AI tools public on the Alternative Investment Market (an LSE sub-exchange), and has since founded, financed or advised more than a dozen technology-focused businesses. Most recently, through Incept Phaedrus, which he co-founded with Mr. Carsten Bressel, he has focused on originating and developing AI compute, data center and associated power infrastructure projects.

Mr. Carsten Bressel will join AXG Digital as Vice President, Strategic and Business Development, with responsibility for strategic transactions, partnerships, joint ventures, project development and capital formation. Mr. Bressel is the Founder and Managing Partner of Phaedrus and co-founder of Incept Phaedrus. His background spans private equity, venture investing, principal investments and strategic transactions, with recent work focused on developing and capitalizing AI infrastructure projects across the United States and Europe.

The appointments, subject to the availability of funding for the projects identified, come as AXG Digital accelerates its AI infrastructure buildout. In August 2026, AXG announced its AI infrastructure expansion targeting more than 100 MW of operational HPC capacity by 2028, with a development pipeline representing more than 1 GW of potential capacity across Europe, the United States, and sub-Arctic markets.

Alongside Mr. Vickery and Mr. Bressel, AXG Digital is adding experienced executives focused on energy and sub-Arctic infrastructure development. AXG Digital is also in advanced discussions with an experienced data center developer regarding a broader development relationship covering the design, construction and operation of its facilities. Together, these capabilities are intended to combine regional operating expertise, energy relationships, data center development and AXG Digital’s expertise in structuring, project finance, capital formation and portfolio management.

AXG Digital’s strategy is focused on developing and acquiring AI-ready infrastructure in markets where access to power, connectivity and capital can create structural advantages. It is intended to combine power-intensive infrastructure development, institutional financing and long-term customer relationships to support the continued expansion of AI and HPC capacity. This infrastructure strategy builds on the Company’s existing AI software and ecosystem foundation, including KOVAR AI, KOVAR Cloud, KOVAR Router, and KOVAR KYA (Know Your Agent).

About SOLOWIN HOLDINGS

SOLOWIN HOLDINGS (Nasdaq: AXG) is a leading global regulated fintech company. Established in 2016, AXG combines blockchain and artificial intelligence technologies to operate a fully compliant dual-token digital economy super platform.

Guided by the mission “Mobilizing Tokens 24/7,” the Company operates two core business pillars: Digital Asset Tokens and AI Tokens. Its offerings span stablecoin issuance and payments, asset tokenization, securities trading and asset management, as well as AI-powered services including cloud infrastructure, Know-Your-Agent verification, and token router.

Through its integrated ecosystem, including AX COIN, AX ONE, FERION, Solomon JFZ, AgentX, and KOVAR, AXG empowers global institutions and investors to capitalize on the rapid growth of the dual-token economy.

For more information, visit www.alloyx.com and follow us on LinkedIn at AXG (Solowin Holdings).

Forward-Looking Statements

Certain statements in this announcement are forward-looking statements, within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These forward-looking statements involve known and unknown risks and uncertainties and are based on the Company’s current expectations and projections about future events that the Company believes may affect its financial condition, results of operations, business strategy and financial needs. The Company has attempted to identify these forward-looking statements by words or phrases such as “may,” “will,” “expect,” “anticipate,” “aim,” “estimate,” “intend,” “plan,” “believe,” “is/are likely to,” “potential,” “continue” or other similar expressions. The Company undertakes no obligation to update or revise publicly any forward-looking statements to reflect subsequent occurring events or circumstances, or changes in its expectations that arise after the date hereof, except as may be required by law. These statements are subject to uncertainties and risks including, but not limited to, the uncertainties related to market conditions and other factors discussed in the Company’s filings with the U.S. Securities and Exchange Commission (the “SEC”) including the “Risk Factors” section of the Company’s most recent Annual Report on Form 20-F as well as in its other reports filed or furnished from time to time with the SEC. Although the Company believes that the expectations expressed in these forward-looking statements are reasonable, it cannot assure you that such expectations will turn out to be correct, and the Company cautions investors that actual results may differ materially from the anticipated results and encourages investors to review other factors that may affect its future results in the Company’s filings with the SEC, which are available for review at www.sec.gov.

For investor and media inquiries, please contact:

SOLOWIN HOLDINGS
Investor Relations Department
Email: ir@solowin.io

Ascent Investor Relations LLC
Tina Xiao
Phone: +1-646-932-7242
Email: investors@ascent-ir.com

Ground Breaking Ceremony

Ground Breaking Ceremony for National Service Center
Ground Breaking Ceremony for National Service Center

National Service Center

National Service Center Building Rendering
National Service Center Building Rendering

ROCK HILL, S.C., Sept. 16, 2026 (GLOBE NEWSWIRE) — Atlas Copco Group has broken ground on a new state-of-the-art North American Service Center in Lancaster County, South Carolina. The custom-built, 355,000-square-foot facility marks a significant investment in the future of the company’s logistics and service operations across North America. Operations are expected to begin at the new facility in June 2027.

The new North American Service Center has been designed to meet the evolving needs of customers and the business for years to come. Selected through a comprehensive site evaluation process, the Lancaster County location provides strategic logistics advantages while offering the flexibility to support future growth.

Once complete, the facility will feature advanced robotics and automation, energy-efficient building design, and modern office space. The North American Service Center plays a critical role in supporting Atlas Copco Group’s customers by managing the warehousing and distribution of compressed air equipment, industrial tools, portable power solutions, and millions of spare parts throughout North America.

The project is a collaboration between Atlas Copco Group, Strategic Capital Partners, DCI Development and Construction, and Alston Construction.

“After more than 15 years in our current facility, it’s time for us to start a new chapter in a new home,” said Andrew Peters, General Manager of the North American Service Center. “Our focus is to build a facility that is ready to meet the future needs of our customers while creating an exceptional workplace for our employees. So many people across our organization have worked tirelessly to make this project a reality, and I want to thank everyone who helped bring us to this milestone.”

The new facility further strengthens Atlas Copco Group’s growing presence in the Lancaster and York County region, where the company first established operations in 1987. The North American Service Center will become the fourth large-scale Atlas Copco Group facility in the region. Collectively, the company employs approximately 1,000 people locally and will occupy more than one million square feet of manufacturing, service, and office space across York and Lancaster counties.

“This investment demonstrates our long-term commitment to the region, our customers, and our employees,” added Peters. “As Atlas Copco Group continues to grow, this facility will help ensure we remain a world-class logistics operation capable of delivering the products and support our customers depend on every day.”

Atlas Copco Group enables technology that transforms the future. We innovate to develop products, services and solutions that are key to our customers’ success. Our four business areas offer technologies for air and gas compression, vacuum and abatement, automated assembly and quality control, mobile energy management and power generation as well as portable and industrial flow technologies. Across the United States, Atlas Copco Group operates more than 160 locations, including 25 production, remanufacturing, and distribution facilities, and employs more than 7,000 people.

www.atlascopcogroup.com

For more information please contact:
Paul Humphreys
Group.usa@atlascopco.com

Photos accompanying this announcement are available at:
https://www.globenewswire.com/NewsRoom/AttachmentNg/bf0ee0dc-a8f5-4a7b-b945-cd8b342f7840
https://www.globenewswire.com/NewsRoom/AttachmentNg/eae89d6d-e188-412d-aa03-1742a7dd1ba3

IR-MED Ltd.

ROSH PINNA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) —

  • Letter of Intent (“LOI”) signed to cooperate in the evaluation, research support, localization, commercialization preparation and regulatory preparation of the PressureSafe™ medical device in Japan.
  • Collaboration addresses a significant potential market need in Japan, which includes more than 36 million people aged 65 and older and approximately 8,000 hospitals, 13,600 long-term care facilities, and 16,000+ home-visit nursing stations.
  • Strategic collaboration combines IR-MED’s infrared spectroscopy technology and proprietary algorithm with Dice Technologies’ capabilities in coordinating clinical evaluation, localization and regulatory preparation activities in Japan.
  • Clinical research and evidence-generation activities are expected to include cooperation with the Department of Plastic Surgery at Kobe University, subject to required ethics review, institutional approvals and separate written arrangements.

IR-MED Ltd. (OTC: IRME) (the “Company” or “IR-Med”), developer of infrared spectroscopy-based medical device technology,, and Dice Technologies Co., Ltd., a leading Japanese healthcare digital transformation and medical IT provider, today announced the signing of a LOI. The LOI sets forth a framework for the parties to cooperate in the evaluation, research support, localization, commercialization preparation and regulatory preparation of IR-MED’s PressureSafe™ device for the Japanese market. Except for certain provisions relating to confidentiality and data protection, intellectual property rights, and device management, return and disposal, the LOI is not intended to create legally binding obligations between the parties.

Ultimately, the partnership is driven by a shared, transformative vision: Build pressure-injury prevention platform — device, AI, and EHR systems unified across hospitals, LTC, and home care nation wide

The parties intend to evaluate PressureSafe™ for use in hospitals, long-term care facilities and home healthcare settings in Japan, with a focus on supporting the assessment of early signs of pressure injuries.

PressureSafe™ is a medical device that uses infrared technology to support the assessment of early changes associated with pressure injuries and skin conditions. It provides real-time, on-site, non-thermal and blood-flow-related indicators intended to support, and not replace, the clinical judgment of nurses and physicians. PressureSafe™ combines infrared spectroscopy with a proprietary algorithm and is intended to support the assessment of early signs of pressure injuries.

Market Need in Japan

Japan is facing an unprecedented demographic and systemic challenge. With an aging population of 36.19 million individuals aged 65 and older (29.4% of the total population), national care expenditures have reached a record ¥11.94 trillion. Concurrently, the healthcare sector is bracing for a projected shortage of hundreds of thousands of nurses and approximately 300,000 care workers.

This convergence of an aging population and severe workforce shortages has driven a significant increase in the prevalence of pressure injuries—particularly in the rapidly growing home care sector, which reports a 1.93% prevalence rate. To address this, Japan requires scalable, technology-assisted care solutions across its approximately 8,000 hospitals (1.2 million beds), 13,600 long-term care facilities (1.0 million residents), and 18,042 home-visit nursing agencies.

A complementary Strategic Synergy

The collaboration between IR-MED and Dice Technologies represents a highly complementary alignment of technological innovation and domestic operational mastery.

  • The Technology & Science Engine (IR-MED): IR-MED brings its proprietary PressureSafe™ sensors, predictive AI algorithms, and a foundation of global clinical data. The technology addresses the crucial “Layer 1” of early risk assessment—sub-epidermal tissue health—providing objective metrics to a field that has historically relied on subjective visual observation.
  • The Domestic Commercial & Integration Leader (Dice Technologies): Dice Technologies will lead and coordinate the evaluation program in Japan. Leveraging an established nationwide footprint serving over 1,000 clinics well-distributed across Japan, Dice Technologies will support Pharmaceuticals and Medical Devices Agency (“PMDA”) consultation preparation and regulatory communications in Japan.. Crucially, Dice Technologies bridges the gap between device and daily workflow by integrating PressureSafe™ data into its existing CareNest platform and domestic Electronic Health Records (“EHR” ), creating a seamless data flow from the hospital to the patient’s home.

Phased Rollout and Clinical Validation

The partnership will execute a highly structured, reverse L-shaped Go-to-Market strategy. The initial phase will focus on real-world evaluations in long-term care (“LTC”) and home-visit settings to generate clinical utility data and user feedback.

Simultaneously, the partners will advance rigorous clinical research and PMDA consultation to support the regulatory pathway for PressureSafe™ in Japan. This validation process will be bolstered by anticipated cooperation with Japanese clinical leaders, including the Department of Plastic and Reconstructive Surgery at Kobe University, subject to required ethics review, institutional approvals and separate written arrangements.

Executive Commentary

Ken Ishiga, President and Representative Director of Dice Technologies Co., Ltd., stated, “Japan’s care crisis cannot be solved with isolated tools. We must unify prevention, observation, and discharge support. By combining IR-MED’s extraordinary ‘sensing the invisible’ technology with our EHR integrations and CareNest platform, we are delivering on our shared vision to build a continuous, patient-centered care infrastructure that supports our overstretched healthcare workforce over the long term.”

“Entering the Japanese market requires more than just groundbreaking technology; it requires a deep integration into the local care ecosystem. In Dice Technologies, we have found the perfect partner,” said Dr. Yaniv Cohen, Interim CEO and Chief Scientific Officer of IR-MED. “Their expertise in medical IT, their impressive footprint serving over 1,000 care facilities, and their ability to navigate PMDA regulations make them the ideal catalyst for PressureSafe™. Together, we are not just evaluating a device; we are working toward a new national standard for objective, preventive care.”

About IR-MED Ltd.

IR-MED Ltd. is developing a cutting-edge infrared spectroscopy and AI analysis platform technology as a basis for point-of-care decision support devices. The infrared spectroscopy technology allows harmless and non-invasive gathering of bio-information from patient blood and tissue. That data is then processed by the Company’s AI-based system to provide healthcare professionals with decision support in the assessment of various medical conditions. PressureSafe™, the Company’s lead platform product, is a handheld device designed to revolutionize the assessment of pressure injuries (PI) affecting skin and underlying tissue regardless of patient skin tone. IR-MED holds patents protecting its innovations in non-invasive tissue assessment.

For more information, visit: https://www.ir-medical.com/

About Dice Technologies Co., Ltd.

Based in Osaka, Japan, Dice Technologies Co., Ltd. specializes in comprehensive digital solutions optimized for clinics, hospitals, and welfare facilities. Backed by a strong national footprint encompassing over 1,000 clinics well-distributed across Japan, the company streamlines healthcare workflows through advanced medical IT systems, seamless electronic medical record (EMR) migrations, medical device distribution, and innovative home assessment applications. Dice Technologies leverages technology and community partnership to reduce operational burdens and build a sustainable healthcare future.

For more information, visit: https://d-technologies.co.jp/

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Statements that are not statements of historical fact, including statements regarding the timing and success of the strategic partnership, the activities contemplated by the LOI, the clinical evaluation results, PMDA regulatory consultations and classification, and commercial acceptance of PressureSafe™ in Japan, are forward-looking statements. These statements are based on management’s current expectations and are subject to risks and uncertainties that could cause actual results to differ materially, including regulatory delays, the non-binding nature of most provisions of the LOI, clinical trial outcomes, competition, and general economic conditions. IR-MED undertakes no obligation to publicly update or revise any forward-looking statements.

Sources:

Statistics Bureau of Japan, Statistical Topics No.146 (published 14 Sep 2025) / MHLW, “Japan’s Population” / MHLW, Report on the Status of Long-Term Care Insurance (Nov 2024) / MHLW, Survey of Long-Term Care Benefit Expenditures FY2024 (published 30 Sep 2025) / MHLW, Survey of Institutions and Establishments for Long-Term Care 2024 (published Dec 2025) / MHLW, Survey of Medical Institutions and Hospital Report 2024 (published 26 Sep 2025; confirmed figures as of 1 Oct 2024)

Investor & Media Contacts:

IR-MED Ltd. Investor Relations Email: contact@ir-medical.com

Website: https://www.ir-medical.com/

Dice Technologies Co., Ltd.

Website: https://d-technologies.co.jp

Contact

IR-MED Ltd. Investor Relations

contact@ir-medical.com

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/a6443cba-0277-42d2-8c5f-ee8361d759d1

The investment for an additional 5% gives Tessera a 15% stake in Motomea with exclusive option to acquire the remainder; secures license to MEA’s drone testing technology

NETANYA, Israel, Sept. 16, 2026 (GLOBE NEWSWIRE) — Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ) (“Tessera” or the “Company”) today announced that it has amended its existing investment agreement for the purchase of an equity stake in M.E.A. Testing Systems Ltd. (“MEA”, “Motomea”), an Israeli company that develops drone-related testing technology, from a 10% to 15% stake. As part of the original agreement, Tessera has secured an exclusive option to acquire the remaining interest in MEA held by its majority shareholder, Motomova Inc. (OTC: MTMV).

Motomea brings over a quarter-century of expertise to the field of electric motor and rotating-machine testing. The company provides testing solutions, including electric propulsion systems for drones, aircraft, robotics, and ground vehicles, to clients across the aerospace, automotive, energy, industrial, and transportation industries. Additionally, Motomea created and patented the industry’s first load-free inertial dynamometer systems, enabling motor performance evaluations during acceleration and deceleration without requiring traditional external mechanical loads.

Under the transaction as amended, Tessera will acquire the 15% interest for $50,000 in cash and 130,000 shares of Tessera common stock, and agreed to issue an additional 65,000 shares, subject to NYSE American approval. Tessera also agreed to an advance to MEA with a convertible loan facility of up to $475,000 to fund working capital and MEA’s drone-related activities. The loan may, at Tessera’s option, be converted into additional equity in MEA, subject to compliance with and approval of NYSE American. Additionally, as part of the closing, Tessera is to receive an exclusive, perpetual, worldwide license for MEA’s technology and know-how.

The option, entitles Tessera to acquire Motomova’s remaining holdings in MEA at a price based on MEA’s audited results for fiscal year 2027.

“Drone threats are now a reality at every site we protect, and effective defense begins with rigorous testing,” said Michael Oster, CEO of Tessera. “MEA adds a critical testing capability to Tessera’s AI-driven security platform, which connects predictive intelligence, sensing, analysis, decisioning and response. Over the long term, what we learn from MEA’s testing will strengthen many of those layers. The transaction structure provides a path to full ownership as MEA scales.”

Following the transaction, MEA will remain majority owned by Motomova, and its management will remain unchanged.

About Tessera Defense and Homeland Security Inc.

Tessera Defense and Homeland Security Inc. (NYSE American: HLSQ) is a physical security technology company providing integrated, bespoke security solutions that connect detection, intelligence and response across complex security environments. The Tessera platform integrates cameras, sensors, detection technologies, AI and other security infrastructure to identify threats, understand events and coordinate response in real time. Tessera provides the technology, hardware and implementation expertise needed to tailor security solutions to the specific requirements of each site, helping customers deploy and optimize integrated security systems across critical infrastructure and homeland security applications.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements regarding the anticipated benefits of the investment in MEA, the integration of MEA’s technology with the Company’s platform, the Company’s intention or ability to exercise its option to acquire the remaining interest in MEA, the conversion of the loan and the issuance of additional shares, and the Company’s strategy and target markets. Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties, including risks related to the Company’s ability to execute its strategy, obtain NYSE American approval for the issuance of additional shares, complete due diligence on MEA, and integrate and commercialize acquired technologies, and those risks described in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for the year ended December 31, 2025, as supplemented by the Form 10-K/A filed April 30, 2026, and its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026. Actual results may differ materially from those expressed or implied. The Company undertakes no obligation to update any forward-looking statement, except as required by law.

Media Contact:
Yair Ohayon, IR & Communication Manager Yairo@thlsq.ai

Total national coverage footprint for PENFS increases to over 120 million covered lives

CARMEL, Ind., Sept. 16, 2026 (GLOBE NEWSWIRE) — NeurAxis, Inc. (“NeurAxis” or the “Company”) (NYSE American: NRXS), a medical technology company commercializing neuromodulation therapies for chronic and debilitating conditions in children and adults, today announced significant new medical policy coverage from a major national health insurer for Percutaneous Electrical Nerve Field Stimulation (“PENFS”). The coverage spans multiple states and represents approximately 18 million health plan members.

NeurAxis’ proprietary PENFS technology, IB-Stim, is FDA-cleared for the treatment of functional abdominal pain associated with irritable bowel syndrome (IBS) and Functional Dyspepsia (FD) including associated nausea symptoms in patients 8 years and older. IB-Stim is a non-invasive neuromodulation device that gently stimulates cranial nerve bundles in the ear to help regulate pain signaling between the gut and the brain. Currently, no FDA-approved drug therapies exist for pediatric patients with abdominal pain related to functional dyspepsia, a significant unmet medical need. In the absence of approved options, off-label prescription drugs are often used, despite limited efficacy data and potential safety concerns—underscoring IB-Stim’s unique position as the only FDA-cleared therapy specifically designed for this large and underserved pain related patient population.

“NeurAxis’ growth is accelerating as we execute on our plans to expand payer coverage, broaden patient access and scale commercialization of IB-Stim,” said Brian Carrico, Chief Executive Officer of NeurAxis. “Securing medical policy coverage for PENFS from one of the nation’s leading health insurers demonstrates tangible progress against these priorities. We are translating our clinical evidence into meaningful coverage gains and actively pursuing additional major national insurers to build on this momentum.

“With a Category I CPT code effective January 1, 2026, and our proprietary PENFS technology incorporated into leading national society clinical practice guidelines, we have established a strong foundation to support continued growth. Our focus is now on converting these achievements into broader physician adoption, increased patient access and sustained commercial expansion. Backed by a strengthened balance sheet and growing payer recognition, we believe NeurAxis is well positioned to deliver significant revenue growth and margin expansion as we continue executing on our strategy.”

About NeurAxis, Inc.

NeurAxis, Inc., is a medical technology company focused on neuromodulation therapies to address chronic and debilitating conditions in children and adults. NeurAxis is dedicated to advancing science and leveraging evidence-based medicine to drive the adoption of IB-Stim, its proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology, by the medical, scientific, and patient communities. IB-Stim is FDA-cleared for functional abdominal pain in irritable bowel syndrome (IBS) and functional dyspepsia, including FD-linked nausea symptoms in patients ages 8 and older. Additional clinical trials of PENFS in multiple pediatric and adult conditions with large unmet healthcare needs are underway. For more information, please visit http://neuraxis.com.

Forward-Looking Statements

Certain statements in this press release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are forward-looking statements. Forward-looking statements are based on management’s current assumptions and expectations of future events and trends, which affect or may affect the Company’s business, strategy, operations or financial performance, and actual results and other events may differ materially from those expressed or implied in such statements due to numerous risks and uncertainties. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified. There are a number of important factors that could cause actual results, developments, business decisions or other events to differ materially from those contemplated by the forward-looking statements in this press release. These factors include, among other things, the conditions in the U.S. and global economy, the trading price and volatility of the Company’s stock, public health issues or other events, the Company’s compliance with applicable laws, the results of the Company’s clinical trials and perceptions thereof, the results of submissions to the FDA, and factors described in the Risk Factors section of NeurAxis’s public filings with the Securities and Exchange Commission (SEC). Because forward-looking statements are inherently subject to risks and uncertainties, you should not rely on these forward-looking statements as predictions of future events. These forward-looking statements speak only as of the date of this press release and, except to the extent required by applicable law, the Company undertakes no obligation to update or revise these statements, whether as a result of any new information, future events and developments or otherwise.

For contraindications, precautions, warnings, and IFU, please see: https://ibstim.com/important-information/.

For important RED information, including indications, precautions, and contraindications, visit: https://red4constipation.com/information/

Contacts:

Company
NeurAxis, Inc.
info@neuraxis.com

For contraindications, precautions, warnings, and IFU, please see: https://ibstim.com/important-information/.

Investor Relations
Lytham Partners
Ben Shamsian
646-829-9701
shamsian@lythampartners.com

Amid rising prices, holiday shoppers are tuning out ads and turning to social earlier for savings, according to new data from Sprout Social

CHICAGO, Sept. 16, 2026 (GLOBE NEWSWIRE) — According to new research from Sprout Social (NASDAQ: SPT), a leading AI-powered Social Intelligence platform, holiday shoppers are taking a more intentional approach to seasonal spending this year and relying on social media throughout their shopping experience. Amid tariff concerns and rising prices, Sprout Social’s Q3 2026 Pulse Survey finds consumers are shopping earlier, seeking discounts, and prioritizing useful social content over targeted ads.

With more than half of consumers (56%) planning to reduce holiday spending because of broader economic conditions, shoppers are looking to make their budgets go further. Nearly 7 in 10 consumers (69%) are concerned about tariff-related price increases, and 36% say they plan to start shopping earlier specifically to avoid them. For brands, that doesn’t mean simply moving holiday campaigns up; it means earning shopper consideration sooner.

Social media is increasingly influencing purchasing decisions, which makes it a critical place to earn attention this holiday season. It has caught up to physical stores, tying as the leading destination for gift discovery among all consumers (46%) and emerging as the clear #1 place for Gen Z to discover products (54%). Social’s role extends beyond discovery and into a purchase platform, as 57% of consumers are open to purchasing directly within social apps.

The research also shows that consumers are looking for more useful content, like a deal or a product demonstration, rather than an influx of brand messaging. Promo codes shared by a company or an influencer are the top driver of holiday purchases followed by posts showing a product in action, while targeted social ads are the least effective driver.

“Because of a tighter economic climate, every purchase carries more weight, making it critical for brands to refine their messaging to ensure it is thoughtful and grounded,” said Scott Morris, CMO at Sprout Social. “As marketers conduct final check-ins on their holiday campaigns, there is a real opportunity to bring alignment across every channel. Brands can support creator partners by encouraging them to keep education and utility at the forefront of their content, while preparing care teams for fast responses. Our data shows shoppers are using social for their entire holiday journey, and delivering genuine utility across that total presence helps brands maximize their ROI while building lasting trust.”

Consumers are closing out their shopping journey on social by heading to platforms like TikTok (50%), Facebook (46%) and Instagram (44%) for customer service, and using direct messages as their preferred way to contact a brand (55%). To meet high expectations for customer care speed, 70% of consumers are comfortable with brands using AI-powered tools to deliver faster responses.

Beyond seasonal shopping, the Q3 2026 Pulse Survey highlights social media’s role in other timely events like upcoming elections:

  • A new newsstand: Ahead of the 2026 midterms, social media serves as a primary news source, standing as the #1 channel for Millennials (38%) and Gen Z (33%).
  • Politicians as influencers: Social posts from politicians have real influence with 55% of all consumers citing that a social post has informed or changed their opinion, while over half of Gen Z report actually changing their mind on an issue.
  • Candidate followings: 45% of social users say they do not follow any politician on social media. Just over a quarter (26%) follow 1-2 politicians.
  • Deepfake concerns: During the election cycle, 84% of voters are concerned about encountering AI-generated deepfakes on social platforms.

For more, including sentiment towards AI disclosure and how brands show up alongside online culture, access the full Q3 2026 Pulse Survey here.

About the data

This consumer survey was conducted online by Glimpse, a global market research firm, on behalf of Sprout Social. Participants included 2,286 social media users across the US, UK and Australia. The survey was conducted from August 11 2026 to August 18 2026.

About Sprout Social

Sprout Social is a leading AI-powered Social Intelligence platform, built on the belief that All Business is Social℠. Powered by Trellis, Sprout’s proprietary AI agent, the platform transforms real-time social media signals into actionable insights that drive business forward. Consistently recognized as a top software by G2, Sprout enables brands to deliver smarter, faster business impact through a suite of solutions including comprehensive publishing and engagement, customer care, influencer marketing, advocacy and predictive media intelligence. Sprout’s software operates across all major social networks and digital platforms. For more information about Sprout Social (NASDAQ: SPT), visit sproutsocial.com.

Social Media Profiles
www.x.com/SproutSocial
www.x.com/SproutSocialIR
www.facebook.com/SproutSocialInc
www.linkedin.com/company/sprout-social-inc-/
www.instagram.com/sproutsocial

Media Contact
Kaitlyn Gronek
Email: pr@sproutsocial.com
Phone: (773) 904-9674

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.